Influenza: The virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients

International Journal of COPD

Volumn 2, Issue 3, 2007, Pages 229-240

  Hovden, Arnt Ove ^a   Cox, Rebecca Jane ^a   Haaheim, Lars Reinhardt ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

COPD; Efficacy; Immune response; Influenza; Vaccine

Indexed keywords

AMANTADINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; MESSENGER RNA; OSELTAMIVIR; PROTEIN M2; RIBONUCLEOPROTEIN; RIMANTADINE; RNA POLYMERASE; SIALIDASE; STEROID; VIRUS RNA; ZANAMIVIR;

ANTIGENICITY; ANTIVIRAL ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DEATH; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EPIDEMIC; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INFLUENZA VIRUS C; INJECTION SITE PAIN; MORBIDITY; NONHUMAN; PANDEMIC; PROTECTION; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; SKIN REDNESS; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

HEALTH EXPENDITURES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NORWAY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VACCINES, INACTIVATED;

EID: 36148972069     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Barry DW, Mayner RE, Staton E, et al. 1976. Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man. Am J Epidemiol, 104:34-46.
2. Basler CF, Reid AH, Dybing JK, et al. 2001. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci USA, 98:2746-51.
3. Baydur A 2004. Influenza vaccination in vulnerable populations. Chest, 125:1971-2.
4. Beyer WE, de Bruijn IA, Palache AM, et al. 1999. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med, 159:182-8.
5. Beyer WE, Palache AM, de Jong JC, et al. 2002. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine, 20:1340-53.
6. Boivin G, Hardy I, Tellier G, et al. 2000. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis, 31:1166-9.
7. Boyer KM, Cherry JD, Welliver RC, et al. 1977. IgM and IgG antibody responses after immunization of children with inactivated monovalent (A/ New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza virus vaccines. J Infect Dis, 136 Suppl:S665-71.
8. Bridges CB, Thompson WW, Meltzer MI, et al. 2000. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. Jama, 284:1655-63.
9. Brokstad KA, Cox RJ, Olofsson J, et al. 1995. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis, 171:198-203.
10. Brokstad KA, Eriksson JC, Cox RJ, et al. 2002. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis, 185:878-84.
11. Brydon EW, Morris SJ, Sweet C. 2005. Role of apoptosis and cytokines in influenza virus morbidity. FEMS Microbiol Rev, 29:837-50.
12. Cameron RJ, de Wit D, Welsh TN, et al. 2006. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med, 32:1022-9.
13. CDC 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 46(RR-8):1-24.
14. CHMP (1997). Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines. CPMP/ BWP/214/96, Circular No. 96-0666:1-22.
15. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. 2005. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis, 11:201-9.
16. Clark A, Potter CW, Jennings R, et al. 1983. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg(Lond), 90:361-70.
17. Colman PM. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci, 3:1687-96.
18. Couch RB. 2003. An overview of serum antibody responses to influenza virus antigens. Dev Biol(Basel), 115:25-30.
19. Cox RJ, Brokstad KA, Zuckerman MA, et al. 1994. An early Immoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine, 12:993-9.
20. Davenport FM, Rott R, Schaefer W. 1960. Physical and biological properties of influenza virus components obtained after ether treatment. J Exp Med, 112:765-82.
21. de Jong JC, Beyer WE, Palache AM, et al. 2000. Mismatch between the 1997/ 1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol, 61:94-9.
22. de Roux A, Marx A, Burkhardt O, et al. 2005. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine.
23. Dowdle WR. 1999. Influenza Avirus recycling revisited. Bull World Health Organ, 77:820-8.
24. Drake JW, Charlesworth B, Charlesworth D, et al. 1998. Rates of spontaneous mutation. Genetics, 148:1667-86.
25. Eisen MB, Sabesan S, Skehel JJ, et al. 1997. Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography. Virology, 232:19-31.
26. Fauquet CM, Mayo MA, Maniloff J, et al. Eds. (2004). Eight report of the International Committee on Taxonomy of Viruses. San Diego, Wien, New York, Academic Press, Elsevier.
27. Fleming DM, Watson JM, Nicholas S, et al. 1995. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect, 115:581-9.
28. Fleming DM, Zambon M, Bartelds AI. 2000. Population estimates of persons presenting to general practitioners with influenza-like illness, 1987-96: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands. Epidemiol Infect, 124:245-53.
29. Francis T Jr, Davenport FM, Hennessy AV. 1953. A serological recapitulation of human infection with different strains of influenza virus. Trans Assoc Am Physicians, 66:231-9.
30. Furminger IGS. 1998. Vaccine production. In Nicholson KG, Webster RG, Hay AL (ed). Textbook of Influenza. Oxford: Blackwell Science. p.324-32.
31. Goldstein MA, Tauraso NM. 1970. Effect of formalin, beta-propiolactone, merthiolate, and ultraviolet light upon influenza virus infectivity chicken cell agglutination, hemagglutination, and antigenicity. Appl Microbiol, 19:290-4.
32. Gorse GJ, O'Connor TZ, Newman FK, et al. 2004. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis, 190:11-19.
33. Gorse GJ, O'Connor TZ, Young SL, et al. 2003. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine, 21:2133-44.
34. Goto H, Kawaoka Y. 1998. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA, 95:10224-8.
35. Govaert TM, Sprenger MJ, Dinant GJ, et al. 1994. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine, 12:1185-9.
36. Govaert TM, Thijs CT, Masurel N, et al. 1994. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. Jama, 272:1661-5.
37. Gross PA, Ennis FA, Gaerlan PF, et al. 1977. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis, 136:623-32.
38. Gross PA, Hermogenes AW, Sacks HS, et al. 1995. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med, 123:518-27.
39. Gross PA, Quinnan GV Jr, Weksler ME, et al. 1989. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine, 7:303-8.
40. Gross PA, Weksler ME, Quinnan GV Jr, et al. 1987. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol, 25:1763-5.
41. Guthrie T, Hobbs CG, Davenport V, et al. 2004. Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J Infect Dis, 190:1927-35.
42. Hannoun C, Megas F, Piercy J. 2004. Immunogenicity and protective efficacy of influenza vaccination. Virus Res, 103:133-8.
43. Harper SA, Fukuda K, Uyeki TM, et al. 2005. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 54(RR-8):1-40.
44. Hehme N, Engelmann H, Kuenzel W, et al. 2004. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res, 103:163-71.
45. Hehme N, Engelmann H, Kunzel W, et al. 2002. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl), 191: 203-8.
46. Hinshaw VS, Bean WJ, Webster RG, et al. 1980. Genetic reassortment of influenza A viruses in the intestinal tract of ducks. Virology, 102:412-9.
47. Hobson D, Curry RL, Beare AS, et al. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond), 70:767-77.
48. Holtzman MJ, Tyner JW, Kim EY, et al. 2005. Acute and chronic airway responses to viral infection: implications for asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2:132-40.
49. Howells CH, Tyler LE. 1961. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. Lancet, 2:1428-32.
50. Huckriede A, Bungener L, Stegmann T, et al. 2005. The virosome concept for influenza vaccines. Vaccine, 23 Suppl 1:S26-38.
51. Hui EK, Barman S, Yang TY, et al. 2003. Basic residues of the helix six domain of influenza virus M1 involved in nuclear translocation of M1 can be replaced by PTAP and YPDL late assembly domain motifs. J Virol, 77:7078-92.
52. Haaheim LR. 2003. Original antigenic sin. A confounding issue? Dev Biol (Basel), 115:49-53.
53. Jefferson T, Rivetti D, Rivetti A, et al. 2005. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet, 366:1165-74.
54. Johnson MK, Stevenson RD. 2002. Management of an acute exacerbation of copd: are we ignoring the evidence? Thorax, 57 Suppl 2:II15-II23.
55. Kawai N, Ikematsu H, Iwaki N, et al. 2003. A prospective, Internet-based study of the effectiveness and safety of influenza vaccination in the 2001-2002 influenza season. Vaccine, 21:4507-13.
56. Keitel WA, Cate TR, Couch RB, et al. 1997. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine, 15:1114-22.
57. Kendal AP, Pereira MS, Skehel J. 1982. Concepts and procedures for laboratory-based influenza surveillance. Publication no. B17-35. Centers for Disease Control, Atlanta, Ga.
58. Kilbourne ED. 1969. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ, 41:643-5.
59. Lamb RA, Krug RM. 1996. Ortomyxoviridae: the viruses and their replication. In:Fields BN, Knipe DM and Howley PM (ed). Fields Virology. Phiadelphia: Lippincott-Raven Publishers. 3rd edition p. 1353-95.
60. McElhaney JE. 2005. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine, 23 Suppl 1:S10-25.
61. McElhaney JE, Hooton JW, Hooton N, et al. 2005. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine, 23:3294-300.
62. McElhaney JE, Meneilly GS, Lechelt KE, et al. 1993. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine, 11:1055-60.
63. Monto AS, Koopman JS, Longini IM, Jr. 1985. Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. Am J Epidemiol, 121:811-22.
64. Murphy BR. 2005. Mucosal immunity to viruses. In Mestecky J, Lamm ME, McGhee JRet al (ed). Mucosal Immunology. London: Elsevier Academic Press. p.799-813.
65. Murphy BR, Chalhub EG, Nusinoff SR, et al. 1973. Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1 (E) influenza A recombinant (H3N2) virus in man. J Infect Dis, 128:479-87.
66. Murphy BR, Webster RG. 1996. Orthomyxoviruses. In Fields BN, Knipe DM and Howley PM (ed). Fields Virology. Philadelphia: Lippincott-Raven Publishers. 3rd edition p. 1397-445.
67. Nguyen-Van-Tam JS. 1998. Epidemiology of influenza. In Nicholson KG, Webster RG and Hay AJ (ed). Textbook of Influenza. Oxford: Blackwell Science. p.181-206.
68. Nichol KL. 1999. Complications of influenza and benefits of vaccination. Vaccine, 17 Suppl 1:S47-52.
69. Nichol KL, Baken L, Nelson A. 1999. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med, 130:397-403.
70. Nichol KL, Lind A, Margolis KL, et al. 1995. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med, 333(14):889-93.
71. Nichol KL, Margolis KL, Wouremna J, et al. 1996. Effectiveness of influenza vaccine in the elderly. Gerontology, 42:274-9.
72. Nichol KL, Nordin J, Mullooly J. 2005. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine.
73. Nicholson KG. 1998. Human influenza. In:Nicholson KG, Webster RG and Hay AJ (ed). Textbook of Influenza. Oxford: Blackwell Science. p.219-64.
74. Niewoehner DE. 2006. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med, 119(10 Suppl 1):38-45.
75. Oxford JS, Bossuyt S, Balasingam S, et al. 2003. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect, 9:1-14.
76. Palache AM. 1997. Influenza vaccines. A reappraisal of their use. Drugs, 54:841-56.
77. Palache AM, Beyer WE, Sprenger MJ, et al. 1993. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine, 11:3-9.
78. Palache AM, van der Velden JW. 1992. Influenza vaccination in asthma. Lancet, 339:741.
79. Palese P. 2004. Influenza: old and new threats. Nat Med, 10(12 Suppl): S82-7.
80. Palladino G, Mozdzanowska K, Washko G, et al. 1995. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol, 69:2075-81.
81. Park CL, Frank AL, Sullivan M, et al. 1996. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics, 98(2 Pt 1):196-200.
82. Perrotta DM, Decker M, Glezen WP. 1985. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol, 122:468-76.
83. Piedra PA, Gaglani MJ, Kozinetz CA, et al. 2005. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine, 23:1540-8.
84. Poole P, Chacko E, Wood-Baker R, et al. 2000. Influenza vaccine for patients with chronic obstructive pulmonary disease. The cochrane database of systematic reviews (3).
85. Portela A, Digard P. 2002. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol, 83(Pt 4):723-34.
86. Potter CW. 1998. Chronicle of Influenza Pandemics. In:Nicholson KG, Webster RG and Hay AJ (ed). Textbook of Influenza. Oxford: Blackwell Science. p.3-18.
87. Potter CW, Jennings R, McLaren C, et al. 1975. A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group. J Hyg(Lond), 75:353-62.
88. Potter J, Stott DJ, Roberts MA, et al. 1997. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis, 175:1-6.
89. Pyhälä R, Haanpaa M, Kleemola M, et al. 2001. Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine, 19:3253-60.
90. Reid AH, Taubenberger JK, Fanning TG. 2001. The 1918 Spanish influenza: integrating history and biology. Microbes Infect, 3:81-7.
91. Ritzwoller DP, Bridges CB, Shetterly S, et al. 2005. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics, 116:153-9.
92. Ruben FL, Akers LW, Stanley ED, et al. 1973. Protection with split and whole virus vaccines against influenza. Arch Intern Med, 132:568-71.
93. Sambhara S, Kurichh A, Miranda R, et al. 2001. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol, 211:143-53.
94. Sapey E, Stockley RA. 2006. COPD exacerbations. 2: aetiology. Thorax, 61:250-8.
95. Shinya K, Ebina M, Yamada S, et al. 2006. Avian flu: influenza virus receptors in the human airway. Nature, 440:435-6.
96. Simonsen L, Viboud C, Taylor R. 2005. Influenza vaccination in elderly people. Lancet, 366:2086.
97. Smith JWG. 1977. Antibody responses and reactogenicity of graded doses of inactivated influenza A/New Jersey/76 whole-virus vaccine in humans. J Infect Dis, 136 Suppl:S475-83.
98. Stephenson I, Nicholson KG, Colegate A, et al. 2003. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine, 21:1687-93.
99. Stephenson I, Nicholson KG, Gluck R, et al. 2003. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet, 362:1959-66.
100. Stephenson I, Nicholson KG, Wood JM, et al. 2004. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis, 4:499-509.
101. Stephenson I, Zambon M. 2002. The epidemiology of influenza. Occup Med (Lond), 52:241-7.
102. Subbarao K, Klimov A, Katz J, et al. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science, 279:393-6.
103. Takada A, Matsushita S, Ninomiya A, et al. 2003. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine, 21:3212-8.
104. Tamura S, Kurata T. 2004. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis, 57:236-47.
105. Tata LJ, West J, Harrison T, et al. 2003. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax, 58:835-9.
106. Taubenberger JK, Reid AH, Lourens RM, et al. 2005. Characterization of the 1918 influenza virus polymerase genes. Nature, 437:889-93.
107. Thursky K, Cordova SP, Smith D, et al. 2003. Working towards a simple case definition for influenza surveillance. J Clin Virol, 27:170-9.
108. Turner DA, Wailoo AJ, Cooper NJ, et al. 2005. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine.
109. Vilkman S, Keistinen T, Tuuponen T, et al. 1996. Age distribution of patients treated in hospital for chronic obstructive pulmonary disease. Age Ageing, 25:109-12.
110. Vu T, Farish S, Jenkins M, et al. 2002. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine, 20:1831-6.
111. Wang CS, Wang ST, Lai CT, et al. 2007. Impact of influenza vaccination on major cause-specific mortality. Vaccine, 25:1196-203.
112. Webster RG, Bean WJ. 1998. Evolution and ecology of influenza viruses: interspecies transmission. In Nicholson KG, Webster RG and Hay AJ (ed). Textbook of influenza. Oxford: Blackwell Science. p. 109-19.
113. Webster RG, Bean WJ, Gorman OT, et al. 1992. Evolution and ecology of influenza A viruses. Microbiol Rev, 56:152-79.
114. WHO 1999. WHO recommended surveillance standards. Geneva, WHO/CDS/CSR/ ISR/99.2, WHO: 1-116.
115. WHO. 2000. Influenza vaccines. Recommendations for the use of inactivated influenza vaccines and other preventive measures. Wkly Epidemiol Rec, 75:281-88.
116. WHO 2002. Draft WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Wkly Epidemiol Rec, 77:394-404.
117. WHO 2005. Influenza pandemic preparedness and response. Geneva, Executive Board rapport - EB115/44.
118. WHO 2005. Influenza vaccines -WHO position paper. Wkly Epidemiol Rec, 80:279-87.
119. Wilde JA, McMillan JA, Serwint J, et al. 1999. Effectiveness of influenza vaccine in health care professionals: a randomized trial. Jama, 281:908-13.
120. Williams WW, Hickson MA, Kane MA, et al. 1988. Immunization policies and vaccine coverage among adults. The risk for missed opportunities. Ann Intern Med, 108:616-25.
121. Wiselka MJ. 1998. Vaccine safety. In Nicholson KG, Webster RG, Hay AJ (ed). Textbook of Influenza. Oxford: Blackwell Science. p.346-57.
122. Wongsurakiat P, Maranetra KN, Gulprasutdilog P, et al. 2004. Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study. Respirology, 9:550-6.
123. Wongsurakiat P, Maranetra KN, Wasi C, et al. 2004. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest, 125:2011-20.
124. Wood JM. 2001. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci, 356:1953-60.
125. Yamashita M, Krystal M, Fitch WM, et al. 1988. Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. Virology, 163:112-22.
126. Yap FH, Ho PL, Lam KF, et al. 2004. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol, 73:617-23.
127. Yewdell J, Garcia-Sastre A. 2002. Influenza virus still surprises. Curr Opin Microbiol, 5:414-18.